AU2002220594A1 - Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus - Google Patents
Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirusInfo
- Publication number
- AU2002220594A1 AU2002220594A1 AU2002220594A AU2059402A AU2002220594A1 AU 2002220594 A1 AU2002220594 A1 AU 2002220594A1 AU 2002220594 A AU2002220594 A AU 2002220594A AU 2059402 A AU2059402 A AU 2059402A AU 2002220594 A1 AU2002220594 A1 AU 2002220594A1
- Authority
- AU
- Australia
- Prior art keywords
- retrovirus
- phyllanthus
- prevention
- treatment
- diseases associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001430294 unidentified retrovirus Species 0.000 title abstract 5
- 241001130943 Phyllanthus <Aves> Species 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229920002824 gallotannin Polymers 0.000 abstract 4
- TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 abstract 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 abstract 1
- 229920002786 Corilagin Polymers 0.000 abstract 1
- JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 abstract 1
- 229920000061 Geraniin Polymers 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 244000173207 Phyllanthus amarus Species 0.000 abstract 1
- CPWYQGWOJMNXGJ-UHFFFAOYSA-N corilagin Natural products OC1C2COC(=O)c3c(O)c(O)c(O)c(O)c3c4c(O)c(O)c(O)c(O)c4C(=O)OC1C(O)C(OC(=O)c5cc(O)c(O)c(O)c5)O2 CPWYQGWOJMNXGJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920001968 ellagitannin Polymers 0.000 abstract 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 abstract 1
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the use a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallotannins for the preparation of a pharmaceutical composition for the prevention or treatment of retrovirus related diseases associated with a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus. Preferably, the retrovirus is a human immunodeficiency virus (HIV). In accordance with the present invention, it is further preferred that said gallotannin or combination of gallotannins is or comprises corilagin and/or geraniin and another ellagitannin. Further preferred is that said Phyllanthus is Phyllanthus amarus.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00121852 | 2000-10-06 | ||
| EP00121852 | 2000-10-06 | ||
| EP01114008 | 2001-06-08 | ||
| EP01114008 | 2001-06-08 | ||
| PCT/EP2001/011524 WO2002028403A1 (en) | 2000-10-06 | 2001-10-05 | Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002220594A1 true AU2002220594A1 (en) | 2002-04-15 |
Family
ID=26071484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002220594A Abandoned AU2002220594A1 (en) | 2000-10-06 | 2001-10-05 | Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040161477A1 (en) |
| EP (1) | EP1333848B1 (en) |
| JP (1) | JP2004513092A (en) |
| AT (1) | ATE322278T1 (en) |
| AU (1) | AU2002220594A1 (en) |
| CA (1) | CA2424869A1 (en) |
| DE (1) | DE60118592T2 (en) |
| ES (1) | ES2261507T3 (en) |
| PT (1) | PT1333848E (en) |
| WO (1) | WO2002028403A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE275413T1 (en) | 2000-10-06 | 2004-09-15 | Phytrix Ag | METHOD FOR PRODUCING PHYLLANTHUS EXTRACTS |
| EP2116253A1 (en) | 2008-05-07 | 2009-11-11 | Phytrix JV, LLC | Novel phyllanthus extract |
| WO2011085454A1 (en) * | 2010-01-18 | 2011-07-21 | Katholieke Universiteit Leuven K.U.Leuven R&D | Gp120 -binding benzene compounds and saccharide compounds |
| KR101604347B1 (en) | 2013-07-01 | 2016-03-17 | 한국생명공학연구원 | Pharmaceutical composition comprising an extract or a fraction of Pistacia weinmannifolia J. Poiss. Ex Franch for preventing or treating inflammatory-related diseases |
| CN103480178B (en) * | 2013-09-30 | 2016-09-28 | 新疆大学 | The method of active component in a kind of Subcritical water chromotagraphy snow chrysanthemum |
| CN103976356B (en) * | 2014-05-07 | 2015-08-26 | 王浩 | A kind of diet food and preparation method thereof |
| CN110665002B (en) * | 2019-10-29 | 2023-01-24 | 信阳市动物疫病预防控制中心 | Antibody preparation for preventing and treating bovine viral diarrhea and preparation method thereof |
| CN111658631A (en) * | 2020-06-11 | 2020-09-15 | 广东盛普生命科技有限公司 | Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine |
| CN112022867B (en) * | 2020-06-18 | 2022-05-13 | 浙江省疾病预防控制中心 | Application of geraniin in preparing anti-novel coronary virus medicine |
| EP3954379A1 (en) * | 2020-08-12 | 2022-02-16 | HFM - Hybrid Fusion Medicals, GmbH | Compositions comprising phyllanthus extract for use in the treatment or prevention of a sars-cov-2 infection and/or at least one symptom of covid-19 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US28754A (en) * | 1860-06-19 | Congress boot | ||
| US33275A (en) * | 1861-09-10 | Improved pipe-joi-nt | ||
| US4388457A (en) * | 1982-02-11 | 1983-06-14 | University Patents, Inc. | Phyllanthostatin compounds |
| US4673575A (en) * | 1985-04-26 | 1987-06-16 | Fox Chase Cancer Center | Composition, pharmaceutical preparation and method for treating viral hepatitus |
| US4937074A (en) * | 1988-03-29 | 1990-06-26 | Fox Chase Cancer Center | Method of treating retrovirus infection |
| WO1990004968A1 (en) * | 1988-10-31 | 1990-05-17 | University Of North Carolina At Chapel Hill | Inhibition of human retroviruses |
| US5854233A (en) * | 1993-09-08 | 1998-12-29 | Pharmacy And Therapeutic Advisory Consultancy Ltd. | Method of treating liver disease and like indications with vasodilating agents |
| US5529778A (en) * | 1994-09-13 | 1996-06-25 | Rohatgi; Surendra | Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same |
| US5571441A (en) * | 1994-11-01 | 1996-11-05 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
| US5648089A (en) * | 1995-07-03 | 1997-07-15 | Shawkat; Tarek | Extract solution and herbal mixture for treatment of hepatitis |
| US6136316A (en) * | 1996-04-17 | 2000-10-24 | Dabur Research Foundation | Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection |
| DE19919585A1 (en) * | 1999-04-29 | 2000-12-07 | Cmi Ag | Use of phyllanthus to treat oxidative stress and other symptoms |
-
2001
- 2001-10-05 ES ES01986262T patent/ES2261507T3/en not_active Expired - Lifetime
- 2001-10-05 DE DE60118592T patent/DE60118592T2/en not_active Expired - Lifetime
- 2001-10-05 US US10/398,379 patent/US20040161477A1/en not_active Abandoned
- 2001-10-05 EP EP01986262A patent/EP1333848B1/en not_active Expired - Lifetime
- 2001-10-05 AT AT01986262T patent/ATE322278T1/en not_active IP Right Cessation
- 2001-10-05 WO PCT/EP2001/011524 patent/WO2002028403A1/en active IP Right Grant
- 2001-10-05 PT PT01986262T patent/PT1333848E/en unknown
- 2001-10-05 AU AU2002220594A patent/AU2002220594A1/en not_active Abandoned
- 2001-10-05 CA CA002424869A patent/CA2424869A1/en not_active Abandoned
- 2001-10-05 JP JP2002532227A patent/JP2004513092A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2261507T3 (en) | 2006-11-16 |
| DE60118592D1 (en) | 2006-05-18 |
| DE60118592T2 (en) | 2007-05-16 |
| JP2004513092A (en) | 2004-04-30 |
| CA2424869A1 (en) | 2002-04-11 |
| ATE322278T1 (en) | 2006-04-15 |
| EP1333848A1 (en) | 2003-08-13 |
| EP1333848B1 (en) | 2006-04-05 |
| WO2002028403A1 (en) | 2002-04-11 |
| US20040161477A1 (en) | 2004-08-19 |
| PT1333848E (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2221370A1 (en) | Composition for treating condyloma acuminata | |
| WO1998001144A2 (en) | Antiviral agents from plant extracts and use for treatment of viral infections | |
| CA2271622A1 (en) | Antiviral agents from plant extracts and use for treatment of viral infections | |
| AU2002220594A1 (en) | Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus | |
| RU2329050C2 (en) | Combination of cytochrome-p450-dependent protease inhibitors | |
| AP9901661A0 (en) | Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases | |
| IL143512A (en) | Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus | |
| AP2000001991A0 (en) | 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases. | |
| YU27203A (en) | Pyrazole derivatives for the treatment of viral diseases | |
| AP2000001971A0 (en) | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine. | |
| BR0209161A (en) | Vaccine composition, vaccination kit, medical treatment method, use of an hpv antigen, and methods for preparing a vaccine and for decreasing HIV viral transmission. | |
| BR9811298A (en) | Use of a physiologically acceptable vanadium compound | |
| CA2163348A1 (en) | Calanolide and Related Antiviral Compounds, Compositions, and Uses Thereof | |
| AU2002219881A1 (en) | Methods and compositions for the treatment of human immunodeficiency virus infection | |
| AU5848794A (en) | Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use | |
| EP4321217A3 (en) | Substituted pyridotriazine compounds and uses thereof | |
| WO2003013424A3 (en) | Use of r-nsaid compounds for anti-hiv treatment | |
| WO1998018477A3 (en) | Pharmaceutical compositions containing lamivudine and zidovudine | |
| CA2155020A1 (en) | Antiviral naphthoquinone compounds, compositions and uses thereof | |
| GR3030852T3 (en) | Calanolide antiviral compounds, compositions and uses thereof. | |
| WO2000072833A3 (en) | Pharmaceutical preparations for inhibiting sphingomyelinase | |
| WO1996001110A3 (en) | Anti-hiv triple combination | |
| WO1997026880A3 (en) | Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients | |
| IL102815A (en) | Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus | |
| AU2880495A (en) | Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |